Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2024 16h05 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2024 16h05 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
01 avr. 2024 07h45 HE
|
Solid Biosciences Inc.
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass.,...
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
27 mars 2024 07h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
13 mars 2024 07h44 HE
|
Solid Biosciences Inc.
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into...
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
07 mars 2024 07h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences to Participate at Upcoming Investor Conferences
06 mars 2024 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
16 janv. 2024 08h00 HE
|
Solid Biosciences Inc.
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision...
Solid Biosciences Announces $109 Million Private Placement
08 janv. 2024 07h09 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
04 janv. 2024 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...